New oncology assays reached tau-level precision in one year instead of five, suggesting the core technology scales faster ...
PMV Pharmaceuticals said on November 4, 2026, that updated results from the pivotal Phase 2 portion of its PYNNACLE trial ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...
PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today ...
The term 'shedding' means 'to cast off' or 'to spill out' in English. Since the widespread use of COVID-19 mRNA vaccines, this term has been used to mean that vaccine-derived components might exit the ...
Chronic inflammation is a recognized risk factor for human cancer at various sites because of persistent oxidative and nitrative tissue damage. Trp53+/- mice show the predisposition to tumor ...
Cancer immunotherapy conference 2026 delivers eight late-breaking studies at SITC 41st Annual Meeting in Phoenix, November ...
Last time, we covered the Japan-originated PAI-1 inhibitor 'TM5614'. This is research that disrupts the mechanism by which ...
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a promising new strategy to make cancer-fighting immune cells ...
Treating human T cells with navtemadlin promoted healthy memory T-cell development and reduced signs of cell exhaustion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results